NCT05838755 - A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

February 17, 2025

Conditions

Pain

Interventions

DRUG

GSK3858279

GSK3858279 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (81)

2196

GSK Investigational Site, Johannesburg

3186

GSK Investigational Site, Torrevieja Alicante

4450

GSK Investigational Site, KwaDukuza

7130

GSK Investigational Site, Somerset West

7530

GSK Investigational Site, Cape Town

14221

GSK Investigational Site, Williamsville

15006

GSK Investigational Site, A Coruña

28078

GSK Investigational Site, Huntersville

28702

GSK Investigational Site, San SebastiAn de Los Rey

29010

GSK Investigational Site, Málaga

29720

GSK Investigational Site, Lancaster

30030

GSK Investigational Site, Decatur

33135

GSK Investigational Site, Miami

33175

GSK Investigational Site, Miami

33401

GSK Investigational Site, West Palm Beach

33777

GSK Investigational Site, Largo

35233

GSK Investigational Site, Daejeon

36207

GSK Investigational Site, Anniston

48145

GSK Investigational Site, Münster

55128

GSK Investigational Site, Mainz

60611

GSK Investigational Site, Chicago

61348

GSK Investigational Site, Bad Homburg

68100

GSK Investigational Site, Mulhouse

75154

GSK Investigational Site, DeSoto

77030

GSK Investigational Site, Houston

77429

GSK Investigational Site, Cypress

78501

GSK Investigational Site, McAllen

85378

GSK Investigational Site, Surprise

90703

GSK Investigational Site, Cerritos

90717

GSK Investigational Site, Lomita

91100

GSK Investigational Site, Corbeil-Essonnes

94574

GSK Investigational Site, Wallerfing

98007

GSK Investigational Site, Bellevue

100032

GSK Investigational Site, Beijing

150001

GSK Investigational Site, Harbin

200032

GSK Investigational Site, Shanghai

414000

GSK Investigational Site, Yueyang

422711

GSK Investigational Site, Bucheon-si

430030

GSK Investigational Site, Wuhan

471003

GSK Investigational Site, Luoyang

510000

GSK Investigational Site, Guangzhou

02451

GSK Investigational Site, Waltham

V3L 3W4

GSK Investigational Site, New Westminster

V5Y 3W2

GSK Investigational Site, Vancouver

R3C 0N2

GSK Investigational Site, Winnipeg

L6S 0C6

GSK Investigational Site, Toronto

M5G 2C4

GSK Investigational Site, Toronto

260-0804

GSK Investigational Site, Chiba

807-8556

GSK Investigational Site, Fukuoka

370-3573

GSK Investigational Site, Gunma

060-0061

GSK Investigational Site, Hokkaido

300-0028

GSK Investigational Site, Ibaraki

211-8533

GSK Investigational Site, Kanagawa

565-0853

GSK Investigational Site, Osaka

321-0204

GSK Investigational Site, Tochigi

321-0974

GSK Investigational Site, Tochigi

322-8550

GSK Investigational Site, Tochigi

103-0027

GSK Investigational Site, Tokyo

104-0031

GSK Investigational Site, Tokyo

143-0015

GSK Investigational Site, Tokyo

160-0008

GSK Investigational Site, Tokyo

42-217

GSK Investigational Site, Częstochowa

81-338

GSK Investigational Site, Gdynia

40-081

GSK Investigational Site, Katowice

40-282

GSK Investigational Site, Katowice

40-648

GSK Investigational Site, Katowice

40-749

GSK Investigational Site, Katowice

60-185

GSK Investigational Site, Skorzewo

96-500

GSK Investigational Site, Sochaczew

02-117

GSK Investigational Site, Warsaw

0184

GSK Investigational Site, Pretoria

120-752

GSK Investigational Site, Seoul

136-705

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

Unknown

GSK Investigational Site, Seoul

08023

GSK Investigational Site, Barcelona

07120

GSK Investigational Site, Palma de Mallorca

WS11 0BN

GSK Investigational Site, Cannock

L9 7AL

GSK Investigational Site, Liverpool

TS17 6EW

GSK Investigational Site, Teesside

LS10 1DU

GSK Investigational Site, West Yorkshire